PLAINSBORO, N.J., Feb. 16, 2011 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today the launch of Trel-XPress™ Demineralized Bone Matrix, expanding its portfolio of bone grafting substitutes for the orthopedic extremity reconstruction surgeon, which includes Integra OS® Osteoconductive Scaffold, a synthetic bone void filler manufactured from beta tri-calcium phosphate and type I bovine collagen; Trel-X(TM), a demineralized bone matrix; and Trel-XC®, a demineralized bone matrix premixed with cancellous bone.
